{"id":"active-oseltamivir","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"2","effect":"Headache"},{"rate":"5","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir is a prodrug that is metabolized to its active form, oseltamivir carboxylate, which selectively inhibits influenza neuraminidase enzymes. By blocking neuraminidase activity, the drug prevents cleavage of sialic acid receptors on the surface of infected cells, trapping newly formed viral particles and preventing their release and subsequent infection of neighboring cells. This reduces viral replication and shortens the duration and severity of influenza infection.","oneSentence":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, preventing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:41.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age"},{"name":"Prophylaxis of influenza A and B in patients ≥1 year of age"}]},"trialDetails":[{"nctId":"NCT07357051","phase":"PHASE3","title":"Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","status":"RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-11-07","conditions":"Respiratory Viral Infection","enrollment":177},{"nctId":"NCT07113392","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","startDate":"2025-08-01","conditions":"Influenza","enrollment":144},{"nctId":"NCT06774859","phase":"PHASE3","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2024-10-27","conditions":"Influenza","enrollment":100},{"nctId":"NCT05170009","phase":"PHASE2, PHASE3","title":"Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2022-04-22","conditions":"Influenza","enrollment":2},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04523090","phase":"PHASE2, PHASE3","title":"Catalysing the Containment of COVID-19","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2020-08-27","conditions":"COVID-19","enrollment":322},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT02369159","phase":"PHASE3","title":"Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2015-03-11","conditions":"Influenza","enrollment":137},{"nctId":"NCT04297462","phase":"NA","title":"Different Regimens in Influenza Postexposure Chemoprophylaxis in Children","status":"UNKNOWN","sponsor":"Centre of Postgraduate Medical Education","startDate":"2016-11-17","conditions":"Influenza, Exposure, Prevention","enrollment":50},{"nctId":"NCT03629184","phase":"PHASE3","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-20","conditions":"Influenza","enrollment":173},{"nctId":"NCT02532283","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-12-11","conditions":"Influenza A Virus","enrollment":102},{"nctId":"NCT03903718","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2020-04-03","conditions":"Influenza","enrollment":""},{"nctId":"NCT03028909","phase":"PHASE2","title":"Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2017-07-24","conditions":"Influenza - Type A Strains","enrollment":""},{"nctId":"NCT00555893","phase":"NA","title":"Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2008-01","conditions":"Influenza","enrollment":194},{"nctId":"NCT02603952","phase":"PHASE1, PHASE2","title":"A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2015-12-07","conditions":"Influenza","enrollment":126},{"nctId":"NCT00298233","phase":"PHASE2","title":"High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"Influenza, Avian Influenza, Severe Influenza","enrollment":326},{"nctId":"NCT01130636","phase":"PHASE4","title":"Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation","status":"COMPLETED","sponsor":"Pharmahungary Group","startDate":"2010-06","conditions":"Influenza","enrollment":6},{"nctId":"NCT00799760","phase":"PHASE3","title":"Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-12","conditions":"Gastric Influenza","enrollment":541},{"nctId":"NCT00980109","phase":"PHASE4","title":"Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-09","conditions":"Influenza","enrollment":390},{"nctId":"NCT00593502","phase":"PHASE4","title":"Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age","status":"COMPLETED","sponsor":"Hospital District of Southwestern Finland","startDate":"2008-02","conditions":"Influenza","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1411,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tamiflu"],"phase":"marketed","status":"active","brandName":"active oseltamivir","genericName":"active oseltamivir","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, preventing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}